Login / Signup

Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.

Elizabeth Lerner PapautskyMartha CarlsonSheila M JohnsonHannah MontagueDeanna J AttaiMaryam B Lustberg
Published in: Breast cancer research and treatment (2022)
There is a need for tailored and effective patient and oncologist information and education on trastuzumab biosimilars, along with improved healthcare communication regarding switching. The discrepancy between patient-reported experiences and oncologist perceptions of the patient experience, suggests a lack of adequate information that may be a challenge not only to the uptake of trastuzumab biosimilars, but to the patient-oncologist relationship.
Keyphrases
  • healthcare
  • patient reported
  • epidermal growth factor receptor
  • health information
  • metastatic breast cancer
  • case report
  • mental health
  • primary care
  • cross sectional
  • affordable care act